Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ 33691011!ä!33691011 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pac+Symp+Biocomput 2021 ; 26 (ä): 131-142 Nephropedia Template TP {{tp|p=33691011|t=2021. SARS-CoV-2 Drug Discovery based on Intrinsically Disordered Regions |pdf=|usr=}}{{33691011}} gab.com Text SARS-CoV-2 Drug Discovery based on Intrinsically Disordered Regions JO: Pac Symp Biocomput http://www.kidney.de/pget.php?&tw=1&pmid=33691011 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a close relative of SARS-CoV-1, causes coronavirus disease 2019 (COVID-19), which, at the time of writing, has spread to over 19.9 million people worldwide. In this work, we aim to discover drugs capable of inhibiting SARS-CoV-2 through interaction modeling and statistical methods. Currently, many drug discovery approaches follow the typical protein structure-function paradigm, designing drugs to bind to fixed three-dimensional structures. However, in recent years such approaches have failed to address drug resistance and limit the set of possible drug targets and candidates. For these reasons we instead focus on targeting protein regions that lack a stable structure, known as intrinsically disordered regions (IDRs). Such regions are essential to numerous biological pathways that contribute to the virulence of various viruses. In this work, we discover eleven new SARS-CoV-2 drug candidates targeting IDRs and provide further evidence for the involvement of IDRs in viral processes such as enzymatic peptide cleavage while demonstrating the efficacy of our unique docking approach. Twit Text FOAVip SARS-CoV-2 Drug Discovery based on Intrinsically Disordered Regions ????Pac Symp Biocomput http://www.kidney.de/pget.php?&tw=1&pmid=33691011 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33691011 #FOAvip English Wikipedia <ref>{{Cite pmid|33691011}}</ref> SARS-CoV-2 Drug Discovery based on Intrinsically Disordered Regions #MMPMID33691011 Mudide A; Alterovitz G Pac Symp Biocomput 2021[]; 26 (ä): 131-142 PMID33691011show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a close relative of SARS-CoV-1, causes coronavirus disease 2019 (COVID-19), which, at the time of writing, has spread to over 19.9 million people worldwide. In this work, we aim to discover drugs capable of inhibiting SARS-CoV-2 through interaction modeling and statistical methods. Currently, many drug discovery approaches follow the typical protein structure-function paradigm, designing drugs to bind to fixed three-dimensional structures. However, in recent years such approaches have failed to address drug resistance and limit the set of possible drug targets and candidates. For these reasons we instead focus on targeting protein regions that lack a stable structure, known as intrinsically disordered regions (IDRs). Such regions are essential to numerous biological pathways that contribute to the virulence of various viruses. In this work, we discover eleven new SARS-CoV-2 drug candidates targeting IDRs and provide further evidence for the involvement of IDRs in viral processes such as enzymatic peptide cleavage while demonstrating the efficacy of our unique docking approach. |*COVID-19[MESH] |*SARS-CoV-2[MESH] |Computational Biology[MESH] |Drug Discovery[MESH]SARS-CoV-2 Drug Discovery based on Intrinsically Disordered Regions (epmc).pdf DeepDyve Pubget Overpricing